An Integrated Network Pharmacology and RNA-seq Approach for Exploring the Protective Effect of Andrographolide in Doxorubicin-Induced Cardiotoxicity
Cardiovascular Drugs and Therapy · 2025
DOI: 10.1007/s10557-024-07555-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Drugs and Therapy, 2025. Verfasst von Sa Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China. Hauptthemen laut MEDLINE: Doxorubicin, Diterpenes, RNA-Seq, Network Pharmacology. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Innovative Research Group Project of the National Natural Science Foundation of China, Fundamental Research Funds for Central Universities of the Central South University, Natural Science Foundation of Hunan Province.
Abstract (Originalsprache)
PURPOSE: Doxorubicin (Dox) is clinically limited due to its dose-dependent cardiotoxicity. Andrographolide (Andro) has been confirmed to exert cardiovascular protective activities. This study aimed to investigate protective effects of Andro in Dox-induced cardiotoxicity (DIC). METHODS: The cardiotoxicity models were induced by Dox in vitro and in vivo. The viability and apoptosis of H9c2 cells and the myocardial function of c57BL/6 mice were accessed with and without Andro pretreatment. Network pharmacology and RNA-seq were employed to explore the mechanism of Andro in DIC. The protein levels of Bax, Bcl2, NLRP3, Caspase-1 p20, and IL-1β were qualified as well. RESULTS: In vitro, Dox facilitated the downregulation of cell viability and upregulation of cell apoptosis, after Andro pretreatment, the above symptoms were remarkably reversed. In vivo, Andro could alleviate Dox-induced cardiac dysfunction and apoptosis, manifesting elevation of LVPWs, LVPWd, EF% and FS%, suppression of CK, CK-MB, c-Tnl and LDH, and inhibition of TUNEL-positive cells. Using network pharmacology, we collected and visualized 108 co-targets of Andro and DIC, which were associated with apoptosis, PI3K-AKT signaling pathway, and others. RNA-seq identified 276 differentially expressed genes, which were enriched in response to oxidative stress, protein phosphorylation, and others. Both network pharmacology and RNA-seq analysis identified Tap1 and Timp1 as key targets of Andro in DIC. RT-QPCR validation confirmed that the mRNA levels of Tap1 and Timp1 were consistent with the sequenced results. Moreover, the high expression of NLRP3, Caspase-1 p20, and IL-1β in the Dox group was reduced by Andro. CONCLUSIONS: Andro could attenuate DIC through suppression of Tap1 and Timp1 and inhibition of NLRP3 inflammasome activation, serving as a promising cardioprotective drug.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
- Institute of Clinical Pharmacy, Central South University, Changsha, 410011, Hunan, China.
- Department of Ophthalmology, the First People's Hospital of Lanzhou City, Lanzhou, 730050, Gansu Province, China.
- Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital, Changsha, 410013, China.
- Department of Gerontology, The Second Xiangya Hospital, Central South University, Changsha, 410011, China. tanshengyu@csu.edu.cn.
ORCID-Profile: Shengyu Tan
Förderung
- Innovative Research Group Project of the National Natural Science Foundation of China
- Fundamental Research Funds for Central Universities of the Central South University
- Natural Science Foundation of Hunan Province
- Health and Family Planning Commission of Hunan Province
- Chinese Pharmaceutical Association Hospital Pharmacy department
- Changsha Science and Technology Project
- Chinese Anti- Cancer Association HER2 target Chinese Research Fund
Zitieren
APA
Liu, S., Liu, J., Su, N., Wei, S., Xie, N., Li, X., Xie, S., Liu, J., Zhang, B., Li, W., & Tan, S. (2025). An Integrated Network Pharmacology and RNA-seq Approach for Exploring the Protective Effect of Andrographolide in Doxorubicin-Induced Cardiotoxicity. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-024-07555-3
Vancouver
Liu S, Liu J, Su N, Wei S, Xie N, Li X, et al. An Integrated Network Pharmacology and RNA-seq Approach for Exploring the Protective Effect of Andrographolide in Doxorubicin-Induced Cardiotoxicity. Cardiovascular Drugs and Therapy. 2025. doi:10.1007/s10557-024-07555-3
BibTeX
@article{Liu2025,
author = {Liu, Sa and Liu, Jiaqin and Su, Nan and Wei, Shanshan and Xie, Ning and Li, Xiangyun and Xie, Suifen and Liu, Jian and Zhang, Bikui and Li, Wenqun and Tan, Shengyu},
title = {An Integrated Network Pharmacology and RNA-seq Approach for Exploring the Protective Effect of Andrographolide in Doxorubicin-Induced Cardiotoxicity},
journal = {Cardiovascular Drugs and Therapy},
year = {2025},
doi = {10.1007/s10557-024-07555-3}
}
EUVIMED